We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $19.6B
1-Year Est. Return 32.64%
This Fund
S&P 500
This Quarter Est. Return
+24.55%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
–
AUM
$8.79B
AUM Growth
+$1.45B
Cap. Flow
-$72.5M
Cap. Flow %
-0.82%
Top 10 Hldgs %
20.48%
Holding
2,420
New
180
Increased
1,163
Reduced
213
Closed
125

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$8.64M
2
WORK
Slack Technologies, Inc.
WORK
+$7.6M
3
ABBV icon
AbbVie
ABBV
+$7.02M
4
TMUS icon
T-Mobile US
TMUS
+$6.46M
5
OTIS icon
Otis Worldwide
OTIS
+$5.52M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$143M
2
EFA icon
iShares MSCI EAFE ETF
EFA
+$19M
3
AGN
Allergan plc
AGN
+$15M
4
MDY icon
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
+$13.8M
5
MUB icon
iShares National Muni Bond ETF
MUB
+$10.6M

Sector Composition

Rank Sector Weight
1 Technology 21.58%
2 Healthcare 14.02%
3 Financials 12.88%
4 Consumer Discretionary 10.4%
5 Industrials 9.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTS
1826
DELISTED
Preferred Apartment Communities, Inc.
APTS
$229K ﹤0.01%
30,156
+11,317
+60% +$82.1K
MITK icon
1827
Mitek Systems
MITK
$838M
$229K ﹤0.01%
23,845
+8,865
+59% +$79.9K
ENVA icon
1828
Enova International
ENVA
$6.48B
$229K ﹤0.01%
15,391
– –
FMBH icon
1829
First Mid Bancshares
FMBH
$1.38B
$229K ﹤0.01%
8,725
+2,916
+50% +$73.1K
APLT
1830
DELISTED
Applied Therapeutics
APLT
$227K ﹤0.01%
6,292
+2,261
+56% +$94.6K
CTMX icon
1831
CytomX Therapeutics
CTMX
$760M
$227K ﹤0.01%
27,302
– –
GRC icon
1832
Gorman-Rupp
GRC
$2.15B
$227K ﹤0.01%
7,300
– –
DTIL icon
1833
Precision BioSciences
DTIL
$205M
$227K ﹤0.01%
907
+332
+58% +$72.7K
FBMS
1834
DELISTED
The First Bancshares, Inc.
FBMS
$226K ﹤0.01%
10,042
+2,170
+28% +$44.1K
CKH
1835
DELISTED
Seacor Holdings Inc.
CKH
$226K ﹤0.01%
7,977
– –
ATHX
1836
DELISTED
Athersys, Inc. Common Stock
ATHX
$226K ﹤0.01%
3,274
+692
+27% +$48.1K
CIR
1837
DELISTED
CIRCOR International, Inc
CIR
$226K ﹤0.01%
8,858
– –
PACB icon
1838
Pacific Biosciences
PACB
$345M
$225K ﹤0.01%
65,353
– –
WMK icon
1839
Weis Markets
WMK
$1.78B
$225K ﹤0.01%
4,490
– –
NPK icon
1840
National Presto Industries
NPK
$998M
$225K ﹤0.01%
2,572
– –
MGPI icon
1841
MGP Ingredients
MGPI
$381M
$225K ﹤0.01%
6,119
– –
EFC
1842
Ellington Financial
EFC
$1.76B
$224K ﹤0.01%
18,985
+3,868
+26% +$39.3K
VSLR
1843
DELISTED
VIVINT SOLAR, INC.
VSLR
$224K ﹤0.01%
22,579
– –
NFBK
1844
DELISTED
Northfield Bancorp
NFBK
$223K ﹤0.01%
19,366
– –
CRNX icon
1845
Crinetics Pharmaceuticals
CRNX
$8.96B
$223K ﹤0.01%
12,732
+6,897
+118% +$118K
AXDX
1846
DELISTED
Accelerate Diagnostics
AXDX
$223K ﹤0.01%
1,469
+346
+31% +$34.1K
BKE icon
1847
Buckle
BKE
$2.33B
$222K ﹤0.01%
14,188
– –
PAR icon
1848
PAR Technology
PAR
$741M
$222K ﹤0.01%
+7,408
New +$162K
TBBK icon
1849
The Bancorp
TBBK
$2.83B
$222K ﹤0.01%
22,607
– –
RVMD icon
1850
Revolution Medicines
RVMD
$44B
$221K ﹤0.01%
7,012
– –
72 73
74
75 76

Similar funds

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
BG
Bahl & Gaynor Cincinnati, Ohio $19.8B AUM 19.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HHII
H&H International Investment Palo Alto, California $20B AUM 9.66% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

MetLife Investment Management's Q2 2020 Portfolio in Review

As of Q2 2020, MetLife Investment Management held 2,420 positions worth $8.79B, up 20% from $7.34B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

MetLife Investment Management's Q2 2020 filing shows 180 new, 1,163 increased, 213 reduced and 125 closed positions. Its largest new stake was DexCom: 96,564 shares worth $9.79M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $143M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

  • MetLife Investment Management's largest Q2 2020 buy was DexCom: 96,564 shares worth $9.79M.
  • MetLife Investment Management added most to AbbVie in Q2 2020, an estimated $7.02M increase.
  • MetLife Investment Management's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $143M.
  • MetLife Investment Management fully exited Allergan plc in Q2 2020, selling an estimated $15M.
  • MetLife Investment Management's ten largest holdings make up 20% of its $8.79B portfolio in Q2 2020.
  • MetLife Investment Management opened 180 new positions and closed 125 in Q2 2020.
  • MetLife Investment Management's portfolio value rose 20% quarter-over-quarter to $8.79B.

Based on MetLife Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.